⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
AIM News
AIM ImmunoTech Inc.
Form 8-K
sec.gov
AIM
AIM ImmunoTech Posts Virtual Investor Key Opinion Leader Segment Spotlighting Ampligen Breakthrough Data in Pancreatic Cancer
globenewswire.com
AIM
Form 8-K
sec.gov
AIM
Form 8-K
sec.gov
AIM
AIM ImmunoTech, Inc. Announces Exercise of Warrants for Approx. $4.2 Million in Gross Proceeds
globenewswire.com
AIM
Pancreatic Cancer Diagnostics Research Report 2026
globenewswire.com
NVDA
AIM
ILMN
GH
AIM ImmunoTech Announces 50% Objective Response Rate (ORR) in UPMC Recurrent Ovarian Cancer Phase 2 Clinical Trial, Suggesting Breakthrough Combination Potential
globenewswire.com
AIM
AIM ImmunoTech Enters Pivotal Value Inflection Phase with Planned Phase 3 Study of Ampligen® in Pancreatic Cancer, Backed by Positive Clinical Signals, Orphan Drug Status, and Global IP
globenewswire.com
AIM
AZN
AIM ImmunoTech Provides Routine Update on Annual Filings
globenewswire.com
AIM
Form 8-K
sec.gov
AIM